



# Your Partner in Vaccine and Infectious Disease Research



VaxTrials is Emmes Group's dedicated unit focused exclusively on vaccine and infectious disease research for commercial biopharma. VaxTrials combines a strong track record of delivering for global pharmaceutical sponsors, often in partnership with leading CROs, with Emmes CRO's full-service capabilities and global footprint.

Together, we offer the expertise and scale to run complex, global, full-service vaccine programs across all phases of clinical development. Our team brings over 35 years of experience in vaccine research, with proven success supporting large-scale trials in diverse geographies and outbreak settings.

Whether you're advancing next-generation vaccines or responding to emerging threats, VaxTrials delivers the strategic insight, operational flexibility, and scientific rigor to move your program forward faster and with higher quality.

## Modernizing clinical research with tech and AI

At VaxTrials we are modernizing clinical research by embedding advanced technologies into research workflows to operate faster, more efficiently, and with higher quality. Our AI-driven innovations include protocol digitization, AI-powered document generation, and patient data tokenization. We are the industry's first native digital and AI specialty CRO built on a proprietary technology and AI platform.

## Services Offerings



Project & Site Management



Clinical Monitoring



Patient Recruitment & Adherence



Medical Monitoring



Safety & Pharmacovigilance



Clinical Supply & Specimen Logistics



Data Management



Biostatistics



Regulatory Services



Medical Writing



Quality Assurance



# What sets us apart?

**Global footprint** - We support infectious disease trials in outbreak settings around the world- backed by local teams, vaccine expertise, and an established investigator network across the Americas, Europe, Africa, and Asia.

**Breadth of experience** - More than 35 years at the forefront of vaccine clinical research, with over 650 trials spanning phases I to IV. From early outbreaks to full-scale pandemics, our experts have helped advance vaccines for some of the world's most pressing infectious diseases, including influenza, RSV, polio, Ebola, COVID-19, and more.

**Project Management** - Providing expert, end-to-end oversight, ensuring every trial runs on time by following a structured and systematic approach.

**Quality Framework** - A proactive, analytical, and risk-based approach to quality, combining robust processes with well-trained teams to deliver reliable results.

**Recruitment & Adherence** - Utilizing participant-first approaches to drive enrollment, boost retention, and keep trials on track and adherent.

---

## Highlights Include

**Phase III Polio Vaccine Trials** - Conducted trials in Latin America for a novel oral polio vaccine, enrolling 6,400 participants and managing 90,000+ visits. The effort enabled the first WHO Emergency Use Listing for a vaccine and supported global distribution of 1+ billion doses.

**Norovirus Vaccine Trial with Global Pharmaceutical Sponsor** - Supported a large-scale norovirus vaccine trial with ~3,500 participants, implementing a recruitment strategy that boosted acute gastroenteritis event detection by 40%, key to powering efficacy analysis.

**Pertussis Vaccine Development with ILiAD** - Provided regional execution support for a Phase II trial of ILiAD's BPZE1 pertussis vaccine candidate, contributing to successful trial operations and positioning the program for advancement to late-phase development.

**Phase I Trial Support for Mid-Sized European Biopharma** - Executed a Phase I trial in Latin America, delivering full operational oversight, rapid site startup, and strong enrollment, helping the client meet critical early-phase milestones.

For additional information on our Vaccine and Infectious Diseases services, please visit [www.vaxtrials.com](http://www.vaxtrials.com)

## Key Statistics

650+

Vaccine and  
Infectious Disease  
Programs

105%

Enrollment  
vs Plan

95%

Subject  
Retention

4%

Protocol  
Deviations